JP2019529570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529570A5 JP2019529570A5 JP2019538565A JP2019538565A JP2019529570A5 JP 2019529570 A5 JP2019529570 A5 JP 2019529570A5 JP 2019538565 A JP2019538565 A JP 2019538565A JP 2019538565 A JP2019538565 A JP 2019538565A JP 2019529570 A5 JP2019529570 A5 JP 2019529570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- release
- activator
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000012190 activator Substances 0.000 claims 11
- 239000011248 coating agent Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000003111 delayed effect Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims 6
- 229960001094 midodrine Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 206010031127 Orthostatic hypotension Diseases 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000012219 Autonomic Nervous System disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010038967 Retrograde ejaculation Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007939 sustained release tablet Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402844P | 2016-09-30 | 2016-09-30 | |
| US62/402,844 | 2016-09-30 | ||
| PCT/US2017/054323 WO2018064490A1 (en) | 2016-09-30 | 2017-09-29 | Compositions of midodrine and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529570A JP2019529570A (ja) | 2019-10-17 |
| JP2019529570A5 true JP2019529570A5 (enExample) | 2020-11-12 |
| JP7057365B2 JP7057365B2 (ja) | 2022-04-19 |
Family
ID=61762934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538565A Active JP7057365B2 (ja) | 2016-09-30 | 2017-09-29 | ミドドリンの組成物およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11202760B2 (enExample) |
| EP (1) | EP3518910A4 (enExample) |
| JP (1) | JP7057365B2 (enExample) |
| WO (1) | WO2018064490A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9789126B2 (en) | 2012-12-21 | 2017-10-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
| US11202760B2 (en) | 2016-09-30 | 2021-12-21 | Xenamed Corp. | Compositions of midodrine and methods of using the same |
| EP3727347A4 (en) * | 2017-12-22 | 2021-10-20 | Xenamed Corp. | LONG-RELEASE MIDODRINE HYDROCHLORIDE COMPOSITIONS AND METHODS OF USE |
| KR20210150495A (ko) * | 2019-04-10 | 2021-12-10 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료 |
| CN110065149B (zh) * | 2019-04-15 | 2021-05-25 | 广西利升石业有限公司 | 生产人造石用的喷涂式脱模剂、制备方法及其使用方法 |
| US20220349008A1 (en) * | 2019-09-09 | 2022-11-03 | The Children's Hospital Of Philadelphia | Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same |
| CN112245399B (zh) * | 2020-10-29 | 2023-02-28 | 西南医科大学 | 一种二氢杨梅素胃漂浮丸剂及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131068A (en) * | 1961-07-24 | 1964-04-28 | American Cyanamid Co | Water-soluble coated edible organic acids |
| EP0423484B1 (de) | 1989-10-16 | 1993-11-03 | PCD-Polymere Gesellschaft m.b.H. | Pressling mit retardierter Wirkstofffreisetzung |
| US5360822A (en) | 1990-02-07 | 1994-11-01 | Nippon Shinyaku Co. Ltd. | Sulfonanilide derivatives and medicine |
| EA200201044A1 (ru) * | 2000-03-31 | 2003-04-24 | Нюкомед Аустриа Гмбх | Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин |
| CN1422150A (zh) * | 2000-03-31 | 2003-06-04 | 尼科米德奥地利有限公司 | 含有米多君和/或脱甘氨酸米多君的控释药物组合物 |
| US6761904B2 (en) | 2000-03-31 | 2004-07-13 | Nycomed Austria Gmbh | Pharmaceutical kit comprising midodrine as active drug substance |
| US20020147232A1 (en) * | 2000-05-26 | 2002-10-10 | Claus Sundgreen | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| CA2733581A1 (en) | 2008-08-15 | 2010-02-18 | Toray Plastics (America), Inc. | Biaxially oriented polylactic acid film with high barrier |
| WO2011038248A1 (en) | 2009-09-25 | 2011-03-31 | Toray Plastics (America), Inc. | Multi-layer high moisture barrier polylactic acid film |
| FR2953410B1 (fr) | 2009-12-09 | 2012-02-24 | Univ Claude Bernard Lyon | Compositions antivirales pharmaceutiques ou veterinaires |
| US20130287823A1 (en) | 2010-12-28 | 2013-10-31 | Hiroko Udagawa | Patch |
| WO2012170676A1 (en) | 2011-06-08 | 2012-12-13 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| JP6522584B2 (ja) | 2013-04-26 | 2019-05-29 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎不全を処置するための組成物及び方法 |
| US20150328246A1 (en) | 2014-05-16 | 2015-11-19 | Vivus, Inc. | Orally administratable formulations for the controlled release of a pharmacologically active agent |
| US11202760B2 (en) | 2016-09-30 | 2021-12-21 | Xenamed Corp. | Compositions of midodrine and methods of using the same |
| EP3727347A4 (en) | 2017-12-22 | 2021-10-20 | Xenamed Corp. | LONG-RELEASE MIDODRINE HYDROCHLORIDE COMPOSITIONS AND METHODS OF USE |
-
2017
- 2017-09-29 US US16/338,317 patent/US11202760B2/en active Active
- 2017-09-29 JP JP2019538565A patent/JP7057365B2/ja active Active
- 2017-09-29 WO PCT/US2017/054323 patent/WO2018064490A1/en not_active Ceased
- 2017-09-29 EP EP17857506.4A patent/EP3518910A4/en active Pending
-
2021
- 2021-11-18 US US17/530,027 patent/US11975103B2/en active Active
-
2024
- 2024-05-06 US US18/656,110 patent/US20250120919A1/en active Pending